Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

2014 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/02/14Seres Health Closes $48 Million Series C Financing
CAMBRIDGE, Mass., Dec. 2, 2014 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, announced today that it has closed its Series C round with $48 million in new investment.  The proceeds from this financing are planned to be used to advance the development of its lead product candidate, SER-109, for prevent... 
Download PDFPrinter Friendly Version
11/17/14Seres Health Appoints Biotechnology Finance Leader Eric Shaff as Chief Financial Officer
CAMBRIDGE, Mass., Nov. 17, 2014 /PRNewswire/ -- Seres Health, Inc., a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that Eric Shaff has joined Seres as its Chief Financial Officer. Mr. Shaff will provide strategic financial guidance for Seres and manage the overall finances of the company. Prior to joining Seres, Mr.... 
Download PDFPrinter Friendly Version
10/06/14Seres Health Appoints Two New Board Members
Financial biotech leaders Richard N. Kender and Dr. Lorence H. Kim join Seres' Board of Directors CAMBRIDGE, Mass., Oct. 6, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced the appointments of Richard N. Kender and Dr. Lorence H. Kim, to the company's board of directors. They each have extensive financial backgrounds which will be beneficial to the Seres team in ach... 
Download PDFPrinter Friendly Version
09/22/14Seres Health Named a "Fierce 15" Biotech Company for 2014
CAMBRIDGE, Mass., Sept. 22, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that it has been named by FierceBiotech as one of 2014's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.  "Amid a great deal... 
Download PDFPrinter Friendly Version
09/08/14Seres Health Presents Final Data for Study of SER-109 in Recurrent Clostridium difficile Infection at ICAAC 2014 Conference
Phase I/II study also demonstrated SER-109 restoration of a diverse, healthy microbiome CAMBRIDGE, Mass., Sept. 8, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced final data for its single-arm, open-label clinical trial of SER-109, its first-in-field, oral microbiome therapeutic. SER-109, a mixture of bacterial spores, is designed for the treatment of recurrent&n... 
Download PDFPrinter Friendly Version
07/14/14Flagship Ventures Adds Pharma Industry Veteran Roger J. Pomerantz, M.D., F.A.C.P. as Senior Partner
CAMBRIDGE, Mass., July 14, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced the appointment of Roger J. Pomerantz, M.D., F.A.C.P., as a Senior Partner. In this role, Dr. Pomerantz will provide strategic counsel and support to the Flagship team as well as to portfolio companies through board and advisory roles. Dr. Pomerantz recently joined as President and Chief Executive Offic... 
Download PDFPrinter Friendly Version
07/07/14Four Boston biotech firms worth watching
Editas Medicine chief executive Katrine S. Bosley (courtesy of the company)It’s already a banner year for biotech in Massachusetts, with 11 firms going public so far — a new record for a single year. In the past few months I’ve been taking a look at some of the companies in the next wave of promising biotechnology in Boston. Here are the details on four of the firms that have especially caught my attention for their efforts to develop game-changing app... 
Download PDFPrinter Friendly Version
06/16/14Microbiome hurry up
... 
Printer Friendly Version
06/09/14Seres Health Closes $10M Series B, Forms Research Collaboration With Mayo Clinic
... 
Printer Friendly Version
06/09/14Seres bags another $10M to gut it out in microbiomics
Biotech Seres Health has raised a quick $10 million B round to support its work in microbiome R&D, appending a partnership with the Mayo Clinic as it advances an infectious disease treatment. The latest round tapped previous backers Flagship Ventures and Enso Ventures alongside new investors at Mayo and Alexandria Venture Investments, coming just 7 months after Seres came out of stealth with a $10.5 million Series A. With the cash, Seres plans to invest in its pipeline of therapies ... 
Download PDFPrinter Friendly Version
06/09/14Seres Health Closes Series B Financing and Enters into a Research Agreement with Mayo Clinic
CAMBRIDGE, Mass., June 9, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, announced today that it has closed its $10 million Series B financing that included existing investors Flagship Ventures and Enso Ventures, and included new investors, Mayo Clinic, Alexandria Venture Investments, and several private investors. The company has a... 
Download PDFPrinter Friendly Version
06/06/14Seres Health: Protein gut check
... 
Printer Friendly Version
06/06/14Former Merck dealmaker takes aim at colon germ
n">An infectious disease expert and former head dealmaker at Merck & Co is racing against his ex-employer and other drugmakers to develop a treatment for a germ that ravages the colon and kills as many as 14,000 Americans each year.Roger Pomerantz on Monday became chief executive officer of privately held Seres Health, whose lead product has proven highly effective against the c. difficile bacteria in early-stage clinical trials. The condition occurs in patients who have been... 
Download PDFPrinter Friendly Version
06/02/14Seres Health Appoints Former Merck Senior Executive, Roger J. Pomerantz, M.D., F.A.C.P., as Chief Executive Officer and Chairman
CAMBRIDGE, Mass., June 2, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, announced today that it has appointed Roger J. Pomerantz, M.D., F.A.C.P. as its President and Chief Executive Officer. Dr. Pomerantz will also remain as Chairman of the Board of Directors of Seres, where he has served since November of 2013. Dr. Pomerantz ... 
Download PDFPrinter Friendly Version
03/25/14Seres Health to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference
CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, today announced that CEO and Co-founder Dr. David Berry will present a company overview at the 21st annual BioCentury Future Leaders in the Biotech Industry Conference. Dr. Berry's ... 
Download PDFPrinter Friendly Version
02/26/14Human Microbiome Therapeutics named a Top 10 emerging technologies for 2014
... 
Printer Friendly Version
01/13/14Seres Health Announces Interim Clinical Data for SER-109 in Recurrent C. difficile
Clinical efficacy observed in first 10 patients CAMBRIDGE, Mass., Jan. 13, 2014 /PRNewswire/ -- Seres Health today announced interim results from a single-arm, open-label clinical trial evaluating its lead Ecobiotic™ candidate, SER-109, a microbial therapeutic developed for the treatment of recurrent Clostridium difficile infection (CDI), a bacterial infection that occurs following administration of antibiotics. So far, the initial data demonstrates an absence of recurrence of CDI ... 
Download PDFPrinter Friendly Version